Commercial launch of TrimX™ to take place via the Kickstarter platform starting April 3rd, 2017
BOUCHERVILLE, QC, March 23, 2017 /CNW Telbec/ - LUMA Life Inc. ("LUMA"), a privately-owned company that develops and commercializes patented and scientifically proven products for the wellness, fitness and aesthetics markets, has recently secured a Class II Medical Device Licence from Health Canada for its lead product, TrimX™. TrimX™ is the first ever regulatory approved and commercially available product in the field of Transcutaneous Electrical Fat Stimulation ("EFS"). The commercial launch of TrimX™ will takes place on April 3rd, 2017 via the Kickstarter crowdfunding platform. TrimX™ is an easy-to-use over-the-counter ("OTC") electrical stimulator that uses the company's novel Adipotronics™ targeted fat loss technology. Over the coming months, the Company hopes to secure further marketing authorizations for its TrimX™ from regulatory agencies in the United States, Europe and other large markets. LUMA Life owns the worldwide rights to the Adipotronics™ technology via an exclusive licence from Aligo Innovation.
"This approval marks the successful completion of 12 years of research and development between a research team at Université du Québec à Montréal (UQAM) and LUMA Life. We are proud to have developed the first ever clinically proven OTC product that enables targeted fat loss and offers a safe, affordable and non-invasive solution to middle-aged people looking to improve their physical appearance." said Luc Mainville, President and CEO of LUMA Life. "Our TrimX™ product targets the multi-billion dollar fitness/aesthetic market. With our supply chain fully implemented, we are excited about this recent news as we prepare for the market launch of TrimX™ via Kickstarter. In addition to Canada, we are actively working on expanding our regulatory approvals and commercial platform to all major territories over the coming months, in order to meet to expected demand to be generated via Kickstarter», added Mr. Mainville.
About the TrimX™ transcutaneous Electrical Fat Stimulator
The development of the TrimX™ electrical stimulator was based on the Adipotronics™ technology to help users eliminate fat from refractory areas that develops over time around the belt/waist line. Adipotronics™ is a patented and clinically proven transcutaneous electrical stimulation technology that triggers the release of fatty acids from the adipocytes (fat cell lipolysis). The fatty acids released into the blood, a phenomenon called lipolysis, are then used as the primary source of energy during exercise. Adipotronics™ is a safe and non-invasive method for inducing fat loss from the most refractory areas, such as the abdomen, hips, and thighs. Contrary to other commercially available fat reduction techniques, Adipotronics™ does not interfere with the viability of the fat cells, keeping the cells intact, which is essential to our health.
Clinically proven results
To validate the clinical efficacy of the Adipotronics™ technology, the Company completed six clinical trials which enrolled a total of 91 volunteers. The last pivotal trial was a triple-blind clinical trial involving 30 middle-aged women conducted at the Ville-Marie Medical Center, of Montreal. The study was led by a multidisciplinary team, including researchers from UQAM, and a researcher from the Naval Health Research Center, California, USA. During the last 5 weeks of a 10-week trial, which involved 3 sessions/ week of 45 minutes of moderate training, the stimulated group lost 466% more targeted fat than the controlled group. Moreover, the study demonstrated that any TrimX™ user had a 270% greater chance of losing fat on stimulated areas when compared to non-stimulated areas. During another trial conducted during the same period, a group of 6 middle-aged men volunteers were stimulated on the abdomen region with TrimX™. The results revealed a reduction of 18% in the fat layer thickness at the stimulated site after the 10-week training.
About Aligo Innovation
Aligo Innovation is the business arm representing several Quebec-based universities, including UQAM. Aligo valorizes research results of universities and their institutional partners from all areas of innovation, including life sciences, human health, animal health, pure and applied sciences, engineering, and information technology and communications. Aligo provides its academic partners and their affiliates with human and financial resources to accelerate and facilitate the commercialization of technologies with high potential and to improve their competitiveness. With its industry knowledge and strong network, Aligo helps bring these discoveries and developing technologies from the academic realm into the business world. Aligo also acts as an engine of economic development, creating spin-offs and improving the competitiveness of existing businesses through the transfer of innovative technologies from its member institutions.
About LUMA Life
LUMA Life is a privately-owned company based in Boucherville, Quebec that develops and commercializes patented and scientifically proven products for the wellness, fitness and aesthetics markets. The company is pioneering research in the field of Electrical Fat Stimulation ("EFS") and intends to leverage the commercial success of its lead product, TrimX™, to further expand its research activities and develop additional therapeutic and commercial applications. The Company commercializes its products directly or via commercial partners.
SOURCE Luma Life
For further information: Public relations: Luc Mainville, 438-826-1426, or [email protected]